Introgen study shows INGN 241 kills chemotherapy-resistant cancer cells

By Lisa Kerner

Erie, Pa., April 4 - Introgen Therapeutics, Inc. and researchers at The University of Texas M. D. Anderson Cancer Center reported that MDA-7, the active component of INGN 241, effectively kills cancer cells that are resistant to the chemotherapeutic agent cisplatin.

Preclinical studies also identified a novel defect in a protein degradation pathway in the cisplatin-resistant cells, which enhances the activity of INGN 241.

According to Introgen, this suggests that INGN 241 may be useful in treating cancers that do not respond to cisplatin.

The data are published in the proceedings of the American Association of Cancer Research for the 97th Annual Meeting held in Washington, D.C.

"These findings are important for the clinical development of INGN 241 and for the treatment of cisplatin-resistant cancers in general," associate vice president, clinical research and development Sunil Chada said in a company news release.

"The data presented today demonstrate that INGN 241 kills ovarian and lung cancer cells that are resistant to cisplatin, suggesting that this investigational therapy may be an important treatment option for patients who develop cisplatin resistance."

Introgen is a biopharmaceutical company focused on the discovery, development and commercialization of targeted molecular therapies for the treatment of cancer and other diseases. The company is located in Austin, Texas.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.